Reina-Campos, Miguel
Heeg, Maximilian http://orcid.org/0000-0002-9594-1377
Kennewick, Kelly
Mathews, Ian T. http://orcid.org/0000-0003-4773-7985
Galletti, Giovanni http://orcid.org/0000-0001-6613-2354
Luna, Vida http://orcid.org/0000-0002-6300-8128
Nguyen, Quynhanh
Huang, Hongling
Milner, J. Justin http://orcid.org/0000-0002-0752-2130
Hu, Kenneth H. http://orcid.org/0000-0002-0294-0202
Vichaidit, Amy
Santillano, Natalie
Boland, Brigid S.
Chang, John T.
Jain, Mohit
Sharma, Sonia http://orcid.org/0000-0002-6556-1963
Krummel, Matthew F. http://orcid.org/0000-0001-7915-3533
Chi, Hongbo http://orcid.org/0000-0002-9997-2496
Bensinger, Steven J. http://orcid.org/0000-0002-9657-4206
Goldrath, Ananda W. http://orcid.org/0000-0002-5900-508X
Article History
Received: 27 June 2022
Accepted: 26 July 2023
First Online: 30 August 2023
Competing interests
: A.W.G. serves on the scientific advisory boards of ArsenalBio and Foundery Innovations. H.C. is a consultant for Kumquat Biosciences. M.F.K. is a founder and shareholder of PIONYR Immunotherapeutic and Foundery Innovations. A provisional patent application has been filed by M.R.-C., G.G. and A.W.G. covering the methods of use of <i>FDFT1</i> and <i>PDSS2</i> manipulation for “Enhancing CAR-T cell performance for cancer immunotherapy” (US Provisional Application Serial No. 63/449,701). The rest of the authors declare no competing interests.